DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo


company name or ticker

Enzon Pharmaceuticals Considers Sale of Assets, Company

Review will analyze selling parts or entirety of company

This Biotech Is Officially for Sale

Enzon is looking into "strategic alternatives" to "maximize shareholder value." We know what that means.

Benzinga's M&A Chatter for Monday December 17, 2012

U.S. HOT STOCKS FUTURES: HOT STOCKS TO WATCH

Enzon Hires Lazard to Review Asset Sales, Sale of the Company

Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for December 06, 2012

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

8 Intriguing Small Cap Biotechnology Companies For Your Consideration

First Pacific Advisors' Top New Buys

First Pacific Advisors' Top New Buys

See More Articles...